Loading
After a 'successful' treatment, cells can sleep for years then relapse. We can barely detect them and cannot target them.
Disseminated tumour cells can persist for years in bone marrow, liver, lung or brain in a non-proliferative state, invisible to imaging and untouched by cytotoxic agents that require cell division. In oestrogen receptor-positive breast cancer, distant recurrence continues at a steady rate for at least twenty years after diagnosis; in colorectal, bladder and lung cancer, detectable circulating tumour DNA after curative surgery predicts relapse with high specificity months before scans. Detection is now possible, but the therapeutic side lags: there are few drugs designed to kill quiescent cells or to keep them asleep, no validated biomarkers of dormancy, and until recently no trials that acted on a molecular residual disease signal. The first ctDNA-guided adjuvant trials show that the signal can be used to de-escalate safely; whether escalation on a positive test improves survival is the open question.
Before cancer spreads, distant organs are changed to become welcoming. A test for those changes would show which organ is at risk while a person still looks cancer-free.
Dormant cancer cells hide in bone marrow. A lab-built model of that hiding place would let us watch them sleep and wake, and test drugs on them.
After surgery for bile duct or gallbladder cancer, a blood test for leftover tumour DNA picks out the people whose cancer will return with hazard ratios of 16 to 26 in two recent cohorts. Nobody has yet tested giving those people more than the standard capecitabine.
A positive leftover-cancer blood test leaves patients frightened and their doctors unsure what to do. A specialist clinic could give them a plan and a trial.
Nearly all cancer drugs are found by killing fast-growing cells. Sleeping cells survive them. A screen designed around dormant cells would find a different class of drug.
Blood tests can now find leftover cancer months before scans, but most patients who test positive have nothing to enrol in. One standing trial per country would fix that.
After surgery or curative treatment, everyone gets regular blood tests for leftover cancer DNA, and the pooled results power forecasts of who will relapse and trials of acting early.
To prove a leftover-cancer test works you need blood taken years before relapse. Collecting and freezing yearly samples now makes every future test testable.
Sleeping cancer cells survive by recycling their own contents. An old malaria drug blocks that recycling and is being tested in people with no visible cancer but detectable residual cells.
Inflammation from infection, injury or surgery can wake dormant cancer cells. Interleukin-1 beta drives that awakening in mouse models of breast cancer, and a cardiovascular trial of the interleukin-1 beta blocker canakinumab saw fewer lung cancers, so blocking it early might keep dormant cells asleep.
Surgery makes some immune cells throw out sticky DNA webs that trap travelling cancer cells and help them settle. Dissolving those webs during the operation might prevent some relapses.
After pre-surgery chemotherapy leaves tumour behind, a blood test for tumour DNA triples the risk of distant relapse when positive. The one trial that acted on it found the DNA usually appeared too late. A trial that tests at surgery with a tumour-informed assay, escalates positives to an antibody-drug conjugate and observes negatives has not been run.
For people at very high cancer risk, install a small population of engineered immune cells that live for years and destroy cells showing early cancer signals before a tumour forms.
Many relapses come from cancer cells that hid dormant for years. Find drugs that either force them awake so chemotherapy kills them, or keep them asleep for life.
Sleeping cancer cells hide in bone marrow where drugs cannot reach them. Pushing them into the bloodstream on purpose, then treating, might clear them.
If a blood test reliably shows whether cancer will come back after surgery, trials could use it instead of waiting years for relapse. Regulators have a process to bless such a test; oncology should use it.
If we cannot kill sleeping cancer cells, we could try to keep them asleep for life. That would turn residual cancer into a harmless passenger.
A few cancer cells survive treatment by going quiet rather than mutating. These survivors are unusually vulnerable to a particular kind of cell death, which a drug could trigger.
Donor immune cells that need no matching could be given as short courses to clear the few cancer cells left after surgery, when the target is smallest.
Leftover-cancer blood tests are being sold faster than evidence that acting on them helps. Paying for them only when the result is recorded would generate the missing evidence.
Vaccines tailored to each patient's tumour mutations are showing real benefit but cost a fortune to make. Automate the whole process so a personalised vaccine costs about as much as a course of chemotherapy.
Individualised mRNA cancer vaccines take weeks to manufacture and work best against minimal residual disease. Making the vaccine at surgery and giving it only when a blood tumour DNA test turns positive matches both facts and concentrates the cost on the minority who will relapse.
Current blood tests for leftover cancer track a few dozen mutations and miss low-level disease. Whole-genome and error-corrected methods integrate signal across thousands of tumour-specific sites plus methylation and fragment features, reaching detection near one part per million in research settings; cost, turnaround and reproducibility are the barriers.
Fluid taken from the lower back contains DNA from brain tumours. Testing it can diagnose, monitor and detect resistance without brain surgery.
Different companies' leftover-cancer blood tests disagree, and there is no shared yardstick. Public reference samples would let anyone check which test actually works.
Cells that survive treatment often change how they make energy, relying on burning fat rather than sugar. Blocking that switch might finish them off.
Cancer cells in the blood wrap themselves in platelets as camouflage. Aspirin may remove that cloak, and it is cheapest to test in the patients at highest risk of relapse.
A blood test after surgery already lets stage II colon cancer patients skip chemotherapy safely. The same test in stage III would spare far more people, and the unproven half, giving more chemotherapy to those who test positive, has so far changed nothing.
Cancer cells enter the blood mostly during rest, so a morning blood test may miss them. Sampling and dosing at the right hour may be a free improvement.
Give a small number of scientists a decade of guaranteed funding to work on a single hard problem such as dormant cancer cells, with no pressure to publish quickly.
A blood test detects lymphoma left behind better than a scan does, and no trial has yet used it to change anyone's treatment.
Extended hormone therapy after breast cancer prevents late recurrence in a minority of women while imposing joint pain, bone loss and sexual side-effects on everyone for a decade. A sensitive residual disease blood test at year five, repeated annually, could show who can safely stop.
A positive blood test tells you cancer is back but not where. Combining whole-body MRI with modern PET tracers may find a single spot that can be zapped.
Together with the JCO Precision Oncology cohort this makes residual disease testing in biliary cancer prognostic to the same degree as in colon cancer. Nobody has yet shown that acting on it helps; that is the trial gap the ideas on this page name.
CEPHEUS extends the quadruplet standard to patients who are not going to transplant, closing the gap between transplant-eligible and ineligible populations. It is also one of the first phase 3 trials to be designed around MRD-negativity as the primary endpoint, which could shorten future myeloma trials by years. Frailer patients still need dose-adapted approaches.
Very wide confidence intervals from a small cohort, but the direction matches the larger 2026 analysis. Gallbladder cancer recurs early and distantly after re-resection, which is exactly the setting where a residual disease test could pick who gets more than capecitabine.
After bladder removal, a blood test can now tell who needs immunotherapy and who can safely be spared it. This is the model for MRD-guided adjuvant therapy across cancers: treat the blood-positive, watch the blood-negative.
Adjuvant treatment for lung cancer is now chosen by genotype. A resected ALK-positive tumour is treated with two years of a tablet instead of four cycles of platinum, which is a different life as well as a different outcome.
E1910 changed the standard of care for adult B-ALL: immunotherapy is now part of front-line consolidation even for patients with no detectable leukaemia, because MRD-negative by flow cytometry does not mean cured. It also demonstrated that a T-cell engager can improve overall survival in a curative setting. Chemotherapy-light or chemotherapy-free regimens built on blinatumomab and inotuzumab are the next step.
Ribociclib is a second adjuvant CDK4/6 option, and the only one with data in node-negative stage II disease. Roughly 3 in 100 patients avoid a relapse or death at three years, so the decision depends heavily on individual risk, tolerance of a three-year oral drug, and cost. Whether the benefit persists after treatment ends, as it did with abemaciclib, needs longer follow-up.
Patients fit enough for cisplatin whose bladder cancer has invaded the muscle wall should now be offered durvalumab with their pre-operative chemotherapy and for about a year after surgery, which improves the chance of cure without compromising the operation. The trial cannot say whether the adjuvant phase is necessary, or how to treat cisplatin-ineligible patients, for whom other trials are ongoing.
Shares Blunt the inflammation that wakes sleeping cancer cells, Ten-year awards for scientists who commit to one hard problem, Eradicate dormant cancer cells: a programme to wake and kill or lock asleep disseminated cells, A blood test for the pre-metastatic niche.
Shares ctDNA-triggered escalation in early TNBC, Formally qualify tumour-DNA blood tests as a surrogate endpoint for adjuvant trials, IMvigor011: using a blood test for leftover cancer to decide who gets immunotherapy after bladder surgery, IMvigor011.
Shares Foresight Diagnostics, Natera, GALAXY: tumour DNA in blood four weeks after bowel cancer surgery predicts relapse tenfold, Intravasation & circulating tumour cells.
Shares Take the blood test, and give the drug, at the right time of day, A blood test for the pre-metastatic niche, Read the spinal fluid to track brain tumours without opening the skull, Reference materials and open proficiency testing for residual disease tests.
Shares Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer, GALAXY: tumour DNA in blood four weeks after bowel cancer surgery predicts relapse tenfold, DYNAMIC: a blood test safely halved chemotherapy use after surgery for stage II colon cancer, CIRCULATE-Japan (GALAXY / VEGA / ALTAIR).
Shares ctDNA monitoring in lymphoma (PhasED-seq, clonoSEQ), Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial, Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer, Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer.
Shares Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer, GALAXY: tumour DNA in blood four weeks after bowel cancer surgery predicts relapse tenfold, IMvigor011, DYNAMIC: a blood test safely halved chemotherapy use after surgery for stage II colon cancer.
Shares Natera, CIRCULATE-Japan (GALAXY / VEGA / ALTAIR), DYNAMIC, Signatera.